Transgene: presents new data at ASCO 2023
TG4050 is based on Transgene's myvac ® platform and benefits from NEC's Artificial Intelligence (AI) technologies.
The new positive data were generated in HPV-negative head and neck cancer patients treated in a Phase I trial currently evaluating TG4050 (NCT04183166). All patients treated with TG4050 in this trial developed a specific immune response, as demonstrated by the results of further immunological analyses, and remain in remission to this day.
Alessandro Riva, Chairman and CEO of Transgene, commented: ' TG4050 is demonstrating its potential to prolong remission in patients after surgery, positioning Transgene as a pioneer in the emerging field of individualized cancer vaccines. The single-agent data we are presenting at ASCO provide a solid basis to accelerate the clinical development of this innovative therapy as an adjuvant treatment for HPV-negative head and neck carcinoma and potentially in other indications. '
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction